New Information Tools From AHRQ Summarize Treatment Options for Infantile Hemangioma
New Information Tools From AHRQ Summarize Treatment Options for Infantile Hemangioma New evidence-based information tools from AHRQ are available to help clinicians, policymakers, parents and caregivers make informed treatment decisions about infantile hemangioma (IH), a birthmark caused by abnormal growth of blood vessels. IH is more commonly found in white babies, girls, and babies born before 37 weeks of pregnancy. A research summary and a free continuing education module are available for clinicians who treat children with IH. A brochure for parents and caregivers of children with IH supports discussions about the benefits and harms of various treatment options including the use of prescription drugs (such as beta-blockers and steroids) and surgery. A research summary for policymakers features considerations for possible health care programs and policy initiatives. The new tools from AHRQ’s Effective Health Care Program are based on a systematic review that evaluated the effectiveness, comparative effectiveness and harms of treatment options for patients with infantile hemangioma. |
No hay comentarios:
Publicar un comentario